Research analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Free Report) in a report issued on Saturday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Ekso Bionics in a research note on Tuesday, July 30th.
Get Our Latest Stock Analysis on EKSO
Ekso Bionics Trading Up 2.0 %
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $5.34 million. During the same period last year, the business posted ($0.31) earnings per share. As a group, analysts predict that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 322.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Five stocks we like better than Ekso Bionics
- How to Calculate Inflation Rate
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Calculate Return on Investment (ROI)
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.